DCF Tool


Tactile Systems Technology Inc – Surgical and Medical Instrument Manufacturing
tactile medical is one of the fastest growing companies in medical devices. as a leader in treatment options for lymphedema and venous ulcer therapies, tactile medical develops advanced home therapy devices to improve health and quality of life for patients with chronic swelling . headquartered in minneapolis, minnesota, we advocate for patient access and serve tens of thousands of patients through a direct national network of product specialists and trainers, reimbursement experts, patient advocates, and clinical staff.
Analysis Results
Intrinsic Value $1.22
Latest Price $13.77
Relative Value 1032% overvalued
Thoughts on this result? Let us know.
Cash Flow (Millions)
Analysis Parameters
New Ticker
Analysis Details
Growth Rate Projection

An exponential growth model was fit to the past cash flow data, giving more weight to more recent years. This model determined a growth rate estimate of -22.4%.

Weighted Average Cost of Capital (WACC)

The calculated WACC is 3.7%. This value is used as the default discount rate.

Value of Future Flows

Assuming a growth rate of -22.4%, the cash flows for the next 5 years are projected.

The present value of each year's flow is adjusted to present value using the discount rate.

Year Future flow (million) Present value (million)
2023 2.44 2.36
2024 1.9 1.76
2025 1.47 1.32
2026 1.14 0.988
2027 0.888 0.74
Terminal Value

Assuming the company was sold after the projection period at an exit multiple of 30, the terminal value of the company would be 26.6 million. This corresponds to a present value of 21.4 million.

Intrinsic Value Per Share

The total present value of the projected cash flows is 7.17 million. Adding in the terminal value gives a total present value of 28.6 million.

There are presently 23.5 million outstanding shares, so the intrinsic value per share is 1.22.

Financial Statements

The following data was to determine the past cash flows.

Current Assets 119,763,000
Current Cash 21,929,000
Current Liabilities 64,330,000
Current Debt 2,968,000
Non-Cash Working Capital (NCWC) 36,472,000
Change in NCWC -17,345,000
EBIT -12,758,000
Tax Provision 2,393,000
Depreciation and Amortization 6,268,000
Capital Expenditure -1,920,000
Unlevered Free Cash Flow -25,755,000
Current Assets 113,547,000
Current Cash 28,229,000
Current Liabilities 34,461,000
Current Debt 2,960,000
Non-Cash Working Capital (NCWC) 53,817,000
Change in NCWC 4,773,000
EBIT -1,762,000
Tax Provision 9,518,000
Depreciation and Amortization 3,681,000
Capital Expenditure -2,355,000
Unlevered Free Cash Flow 4,337,000
Current Assets 123,613,000
Current Cash 47,855,000
Current Liabilities 26,714,000
Current Debt 0
Non-Cash Working Capital (NCWC) 49,044,000
Change in NCWC 7,371,000
EBIT -3,628,000
Tax Provision -1,641,000
Depreciation and Amortization 2,794,000
Capital Expenditure -2,291,000
Unlevered Free Cash Flow 4,246,000
Current Assets 108,335,000
Current Cash 45,234,000
Current Liabilities 21,428,000
Current Debt 0
Non-Cash Working Capital (NCWC) 41,673,000
Change in NCWC 18,673,000
EBIT 10,498,000
Tax Provision 158,000
Depreciation and Amortization 3,538,000
Capital Expenditure -5,446,000
Unlevered Free Cash Flow 27,113,958
Current Assets 84,961,000
Current Cash 45,885,000
Current Liabilities 16,076,000
Current Debt 0
Non-Cash Working Capital (NCWC) 23,000,000
Change in NCWC 4,559,000
EBIT 2,990,000
Tax Provision -3,147,000
Depreciation and Amortization 3,635,000
Capital Expenditure -4,196,000
Unlevered Free Cash Flow 6,988,000
Current Assets 76,872,000
Current Cash 43,912,000
Current Liabilities 14,519,000
Current Debt 0
Non-Cash Working Capital (NCWC) 18,441,000
Change in NCWC 9,696,000
EBIT 3,898,000
Tax Provision -1,665,000
Depreciation and Amortization 1,849,000
Capital Expenditure -3,746,000
Unlevered Free Cash Flow 11,697,000

This analysis is provided for informational purposes only and does not constitute financial or investing advice. For more information on the advantages and limitations of DCF analysis see background. This information is provided on an "as is" basis. No warranty, expressed or implied, is made regarding accuracy, adequacy, completeness, legality, reliability or usefulness of any information. By using this site you agree that under no circumstances shall Valuation Tools LLC be held liable for any loss or damage caused by information obtained from this website including any articles, data, videos, its social media accounts, or any other materials.